McKesson Corporation (MCK)
NYSE:MCK
Want to see MCK full AI Analyst Report?
MCK Stock Chart & Stats
$760.57
$1.72(0.29%)
At close: 4:00 PM EST
$760.57
$1.72(0.29%)
Day’s Range― - ―
52-Week Range$637.00 - $999.00
Previous CloseN/A
Volume137.88K
Average Volume (3M)1.14M
Market Cap
$92.09B
Enterprise Value$96.72B
Total Cash (Recent Filing)$3.98B
Total Debt (Recent Filing)$8.61B
Price to Earnings (P/E)22.5
Beta0.23
Next Earnings
Aug 05, 2026EPS Estimate
9.6Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)38.64
Shares Outstanding120,204,050
10 Day Avg. Volume1,359,656
30 Day Avg. Volume1,141,074
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)-49.24
Price to Sales (P/S)0.27
P/FCF Ratio18.70
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue0.24
Enterprise Value/Gross Profit6.65
Enterprise Value/Ebitda13.43
Forecast
1Y Price Target
$946.91Price Target Upside24.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)44.26
Revenue Forecast (FY)$433.69B
Bulls Say, Bears Say
Bulls Say
Biosimilars ExpansionAddition of a pegfilgrastim biosimilar and a partnership with a contract manufacturer position the private-label unit to capture higher-margin biosimilar sales and steer oncology volume through the company’s provider network.
Cost ReductionsCost reductions in the prescription technology unit, including workforce reductions, should improve operating margins by lowering ongoing operating expenses.
Earnings And GuidanceBeats and raises on adjusted earnings and consolidated operating income, combined with raised guidance for oncology and prescription technology operating profit, indicate stronger core performance and expected revenue momentum.
Bears Say
Cash-pay Prescription ShiftRapid growth in cash-pay GLP-1 prescriptions is shifting volume away from insurance, reducing prior authorizations and weakening revenue for the prescription technology segment.
Medical-surgical Demand WeaknessWeaker medical-surgical results driven by lower physician office volume and a milder illness season create a headwind for that segment and drag on overall performance.
Pricing PressureDeclining cash prices for GLP-1 drugs are lowering reimbursement baselines and may erode the economics per prescription processed through insurance.
McKesson News
MCK FAQ
What was McKesson Corporation’s price range in the past 12 months?
McKesson Corporation lowest stock price was $637.00 and its highest was $999.00 in the past 12 months.
What is McKesson Corporation’s market cap?
McKesson Corporation’s market cap is $92.09B.
When is McKesson Corporation’s upcoming earnings report date?
McKesson Corporation’s upcoming earnings report date is Aug 05, 2026 which is in 71 days.
How were McKesson Corporation’s earnings last quarter?
McKesson Corporation released its earnings results on May 07, 2026. The company reported $11.69 earnings per share for the quarter, beating the consensus estimate of $11.565 by $0.125.
Is McKesson Corporation overvalued?
According to Wall Street analysts McKesson Corporation’s price is currently Undervalued.
Does McKesson Corporation pay dividends?
McKesson Corporation pays a Quarterly dividend of $0.82 which represents an annual dividend yield of 0.37%. See more information on McKesson Corporation dividends here
What is McKesson Corporation’s EPS estimate?
McKesson Corporation’s EPS estimate is 9.6.
How many shares outstanding does McKesson Corporation have?
McKesson Corporation has 120,204,050 shares outstanding.
What happened to McKesson Corporation’s price movement after its last earnings report?
McKesson Corporation reported an EPS of $11.69 in its last earnings report, beating expectations of $11.565. Following the earnings report the stock price went down -2.474%.
Which hedge fund is a major shareholder of McKesson Corporation?
Currently, no hedge funds are holding shares in MCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
McKesson Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$946.91 (24.50% Upside)
$946.91 (24.50% Upside)
Blogger Sentiment
Bullish
MCK Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 323.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $328.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.22%
12-Months-Change
Fundamentals
Return on Equity
-265.44%
Trailing 12-Months
Asset Growth
9.56%
Trailing 12-Months
Company Description
McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
MCK Company Deck
MCK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
McKesson reported a strong fiscal 2026 with double-digit revenue, operating profit and EPS growth, robust cash generation and material progress on strategic initiatives (oncology expansion, biopharma scale, supply chain modernization, and Medical‑Surgical separation). The company is returning significant capital to shareholders and reaffirmed long‑term targets. Offsetting risks include branded pricing pressure (IRA effects), sequential GLP‑1 volatility, ongoing integration and corporate expense investments, and near‑term cash flow/interest impacts related to separation financing. On balance the positives (broad-based growth, margin expansion, cash returns, strategic progress) outweigh the negatives, though the business faces near-term variability and execution/approval risks tied to the Medical‑Surgical separation.View all MCK earnings summariesMCK Revenue Breakdown
83.45% North American Pharmaceutical
12.00% Oncology & Multispecialty
1.44% Prescription Technology Solutions
2.85% Medical-Surgical Solutions
0.26% Other
MCK Stock 12 Month Forecast
Average Price Target
$946.91
▲(24.50% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
23.93% Mutual Funds
14.58% Other Institutional Investors
38.06% Public Companies and Individual Investors